Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 182

1.

[Probabilistic cost-effectiveness analysis of oral eletriptan in the treatment of acute migraine in Portugal].

Félix JM, Inês MS, Acosta CM.

Acta Med Port. 2005 Jan-Feb;18(1):77-87. Epub 2005 Mar 11. Portuguese.

2.

Rizatriptan: a pharmacoeconomic review of its use in the acute treatment of migraine.

McCormack PL, Foster RH.

Pharmacoeconomics. 2005;23(12):1283-98. Review.

PMID:
16336021
3.

An economic evaluation of rizatriptan in the treatment of migraine.

Thompson M, Gawel M, Desjardins B, Ferko N, Grima D.

Pharmacoeconomics. 2005;23(8):837-50.

PMID:
16097844
4.

Economic analysis of triptan therapy for acute migraine: a Medicaid perspective.

Mullins CD, Subedi PR, Healey PJ, Sanchez RJ.

Pharmacotherapy. 2007 Aug;27(8):1092-101.

PMID:
17655509
5.

Eletriptan: a review of its use in the acute treatment of migraine.

McCormack PL, Keating GM.

Drugs. 2006;66(8):1129-49. Review.

PMID:
16789799
6.

The cost-effectiveness of oral triptan therapy in Sweden.

Ramsberg J, Henriksson M.

Cephalalgia. 2007 Jan;27(1):54-62.

PMID:
17212684
7.
8.

Eletriptan.

Sandrini G, Perrotta A, Tassorelli C, Nappi G.

Expert Opin Drug Metab Toxicol. 2009 Dec;5(12):1587-98. doi: 10.1517/17425250903410226. Review.

PMID:
19929447
9.

[Triptanes in the treatment of migraine. A review based on three Cochrane reviews].

Tfelt-Hansen P, Iversen HK.

Ugeskr Laeger. 2006 May 8;168(19):1850-3. Review. Danish. No abstract available.

PMID:
16756800
10.

Spotlight on eletriptan in migraine.

McCormack PL, Keating GM.

CNS Drugs. 2006;20(11):961-4. Review.

PMID:
17044732
11.

Safety and efficacy of eletriptan in the treatment of acute migraine.

Takiya L, Piccininni LC, Kamath V.

Pharmacotherapy. 2006 Jan;26(1):115-28. Review.

PMID:
16506353
12.

[Economic evaluation of acute migraine attack treatment with triptans in Spain].

Gracia-Naya M, Rejas Gutiérrez J, Latorre Jiménez A, González Garcia P.

Neurologia. 2005 Apr;20(3):121-32. Spanish.

PMID:
15815947
13.

Oral serotonin receptor agonists: a review of their cost effectiveness in migraine.

Lofland JH, Nash DB.

Pharmacoeconomics. 2005;23(3):259-74. Review.

PMID:
15836007
14.

Cost-effectiveness of almotriptan and rizatriptan in the treatment of acute migraine.

Williams P, Reeder CE.

Clin Ther. 2003 Nov;25(11):2903-19.

PMID:
14693315
15.

Cost-effectiveness of oral triptans for acute migraine: mixed treatment comparison.

Asseburg C, Peura P, Oksanen T, Turunen J, Purmonen T, Martikainen J.

Int J Technol Assess Health Care. 2012 Oct;28(4):382-9. doi: 10.1017/S0266462312000517. Epub 2012 Sep 26.

PMID:
23013610
17.

Using patient-centered endpoints to determine the cost-effectiveness of triptans for acute migraine therapy.

Kelman L, Von Seggern RL.

Am J Ther. 2006 Sep-Oct;13(5):411-7. Review.

PMID:
16988536
18.

The cost effectiveness of stratified care in the management of migraine.

Williams P, Dowson AJ, Rapoport AM, Sawyer J.

Pharmacoeconomics. 2001;19(8):819-29.

PMID:
11596834
19.

Effectiveness of eletriptan in reducing time loss caused by migraine attacks.

Wells NE, Steiner TJ.

Pharmacoeconomics. 2000 Dec;18(6):557-66.

PMID:
11227394

Supplemental Content

Support Center